wellness

Nature Medicine, Published online: 29 September 2025; doi:10.1038/s41591-025-03944-9

A post hoc analysis of a multicentre, randomised trial showed that prediabetes remission is possible without total weight loss—providing weight is distributed to subcutaneous deposits as opposed to visceral ones.

Nature Medicine, Published online: 29 September 2025; doi:10.1038/s41591-025-03918-x

In the proof-of-concept phase 2 ROME trial, comprehensive genomic profiling followed by molecular tumor board evaluation and randomization of patients with metastatic solid cancer to receive personalized therapy or standard of care led to a significantly higher objective response rate and longer progression-free survival in patients who received personalized therapy.

Nature Medicine, Published online: 29 September 2025; doi:10.1038/s41591-025-03977-0

A phase 3 trial found that VER-01, a full-spectrum cannabis extract, reduces chronic low back pain, improves physical function and sleep and shows no signs of dependence or withdrawal.

Nature Medicine, Published online: 29 September 2025; doi:10.1038/s41591-025-03948-5

The US Food and Drug Administration (FDA) is at a crossroads. There is an urgent need to strengthen the integrity of drug approvals and rejections by diffusing the decision-making authority of individual officials and improving transparency when disagreements arise.

Nature Medicine, Published online: 26 September 2025; doi:10.1038/d41591-025-00060-6

Patients with obesity achieved significant weight loss and cardiometabolic benefits with oral orforglipron — offering a potential alternative to injectable GLP-1 receptor agonists.

Nature Medicine, Published online: 26 September 2025; doi:10.1038/s41591-025-03952-9

Despite mixed efficacy outcomes, a phase 1/2 umbrella trial brings the glioblastoma field closer to a new era of diagnostic precision and targeted therapy.

Nature Medicine, Published online: 25 September 2025; doi:10.1038/s41591-025-03951-w

In a randomized trial of patients with a previous myocardial infarction and with residual inflammation, a monoclonal antibody targeting the LOX-1 receptor, thought to contribute to atherosclerotic plaque progression and inflammation, reduced soluble LOX-1 and interleukin-6 levels but did not lead to a substantial reduction in coronary plaque volume.

Nature Medicine, Published online: 24 September 2025; doi:10.1038/s41591-025-03937-8

In a phase 1 trial, the co-infusion of CD19-targeting and BCMA-targeting CAR-T cells in adults with treatment-refractory lupus was safe and had promising efficacy, with most patients achieving remission after 3 months.

Nature Medicine, Published online: 24 September 2025; doi:10.1038/s41591-025-03967-2

In the randomized phase 1b/2 Morpheus-Melanoma trial evaluating various neoadjuvant immune checkpoint inhibitor regimens in patients with resectable stage III melanoma, tobemstomig, an anti-PD-1/anti-LAG-3 bispecific antibody, showed the highest pathologic response rate with a better safety profile than the standard treatment approach of ipilimumab plus nivolumab.

Nature Medicine, Published online: 24 September 2025; doi:10.1038/d41591-025-00059-z

Smoke from 2023 Canadian wildfires led to increased PM2.5 exposure across North America and Europe, leading to thousands of acute and chronic deaths.